721 related articles for article (PubMed ID: 16912518)
21. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
[TBL] [Abstract][Full Text] [Related]
22. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; DoĊegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
23. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
25. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
26. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
27. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ
Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873
[TBL] [Abstract][Full Text] [Related]
28. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
30. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
31. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Noguchi T; Tanimoto K; Shimokuni T; Ukon K; Tsujimoto H; Fukushima M; Noguchi T; Kawahara K; Hiyama K; Nishiyama M
Clin Cancer Res; 2004 Oct; 10(20):7100-7. PubMed ID: 15501990
[TBL] [Abstract][Full Text] [Related]
32. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH
Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910
[TBL] [Abstract][Full Text] [Related]
33. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
[TBL] [Abstract][Full Text] [Related]
34. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
36. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
37. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
38. Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL; McLeod HL
Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
40. Dihydropyrimidine dehydrogenase deficiency in an Indian population.
Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
